Core Viewpoint - The market anticipates New Jersey Resources (NJR) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - NJR is expected to post quarterly earnings of $1.65 per share, reflecting a year-over-year increase of +17.9%, and revenues are projected to be $731.72 million, up 11.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 750% lower in the last 30 days, indicating a significant reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.21%, indicating a likelihood of beating the consensus EPS estimate [10][11]. Historical Performance - In the last reported quarter, NJR exceeded the expected earnings of $1.14 per share by delivering $1.29, resulting in a surprise of +13.16%. Over the last four quarters, the company has beaten consensus EPS estimates two times [12][13]. Investment Considerations - While NJR appears to be a strong candidate for an earnings beat, other factors should also be considered when making investment decisions [14][16].

Company Overview - ADC Therapeutics SA (ADCT) is anticipated to report a year-over-year increase in earnings due to higher revenues for the quarter ended March 2025, with a consensus outlook indicating a quarterly loss of $0.38 per share, reflecting a +32.1% change from the previous year [1][3] - Expected revenues for ADC Therapeutics are projected at $18.15 million, which is a slight increase of 0.6% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 8.33% higher in the last 30 days, indicating a reassessment by analysts of their initial estimates [4] - The Most Accurate Estimate for ADC Therapeutics aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a positive ESP being a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [6][8] - ADC Therapeutics currently holds a Zacks Rank of 3, making it challenging to predict a definitive earnings beat [11] Historical Performance - In the last reported quarter, ADC Therapeutics was expected to post a loss of $0.35 per share but actually reported a loss of $0.29, resulting in a surprise of +17.14% [12] - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Cardiff Oncology (CRDF) is expected to report a loss of $0.19 per share for the same quarter, indicating a year-over-year change of +13.6% [17] - Cardiff Oncology's revenue is projected to be $0.17 million, down 19.1% from the previous year, but it has an Earnings ESP of 24.32% and a Zacks Rank of 2, suggesting a higher likelihood of beating the consensus EPS estimate [18]

Core Viewpoint - Williams Companies, Inc. is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.57 per share, reflecting a year-over-year decrease of 3.4%, while revenues are projected to reach $3.14 billion, representing a 13.4% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 3.8%, indicating a reassessment by analysts regarding the company's earnings outlook [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for the company is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.35%, suggesting a bearish sentiment among analysts [10][11]. Historical Performance - In the last reported quarter, the company exceeded the expected earnings of $0.45 per share by delivering $0.47, achieving a surprise of +4.44%. Over the past four quarters, the company has consistently beaten consensus EPS estimates [12][13]. Investment Considerations - Despite the historical performance of beating estimates, the current combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict a positive earnings surprise for the upcoming report [11][16].

Core Viewpoint - The Beachbody Company, Inc. (BODI) is expected to report a year-over-year increase in earnings despite lower revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The company is projected to post a quarterly loss of $1.33 per share, reflecting a year-over-year change of +30.7% [3]. - Revenues are anticipated to be $63.1 million, down 47.4% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 11.01% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with positive readings being more predictive of earnings beats [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have shown a nearly 70% success rate in delivering positive surprises [8]. Historical Performance - In the last reported quarter, the company was expected to post a loss of $2.88 per share but delivered a loss of $1.89, resulting in a surprise of +34.38% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - The Beachbody Company does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, but other factors should also be considered for investment decisions [16].

Core Viewpoint - Certara, Inc. is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with earnings expected at $0.13 per share, reflecting a 30% increase, and revenues projected at $106 million, a 9.7% rise from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for May 5, and the stock may experience upward movement if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 2.63% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, which complicates predictions of an earnings beat [10][11]. - Certara's Zacks Rank is currently 3 (Hold), which does not strongly indicate a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Certara exceeded the expected earnings of $0.13 per share by delivering $0.15, resulting in a surprise of +15.38% [12]. - Over the past four quarters, Certara has beaten consensus EPS estimates two times [13]. Industry Context - Exact Sciences, a peer in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings of $0.37 per share, reflecting a 26% year-over-year increase, with revenues projected at $689.35 million, an 8.1% increase [17]. - Exact Sciences has an Earnings ESP of 61.75% and a Zacks Rank of 3, indicating a higher likelihood of surpassing the consensus EPS estimate [18].

The market expects Diamondback Energy (FANG) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

Core Viewpoint - Vertex Pharmaceuticals (VRTX) is expected to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended March 2025, with the consensus outlook being crucial for assessing the company's earnings picture [1] Earnings Expectations - The upcoming earnings report is anticipated to be released on May 5, 2025, with a consensus EPS estimate of $4.22, reflecting an 11.3% decrease year-over-year, while revenues are projected to be $2.82 billion, up 4.8% from the previous year [3][2] - A positive surprise in earnings could lead to a stock price increase, while a miss could result in a decline [2] Estimate Revisions - The consensus EPS estimate has been revised 0.15% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4] - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that a positive or negative reading can indicate the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [6][7] Earnings Surprise History - Vertex has beaten consensus EPS estimates in two out of the last four quarters, with a recent surprise of -0.25% when it reported earnings of $3.98 against an expectation of $3.99 [12][13] Industry Comparison - Another company in the same industry, Travere Therapeutics (TVTX), is expected to report a loss of $0.55 per share, which represents a year-over-year increase of 68.8%, with revenues projected at $74.33 million, up 79.7% from the previous year [17] - Travere has an Earnings ESP of 11.18% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate, despite not having beaten estimates in the last four quarters [18]

Group 1: Earnings Performance - Citizens Community Bancorp, Inc. (CZWI) reported quarterly earnings of $0.32 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, but down from $0.39 per share a year ago, representing an earnings surprise of 18.52% [1] - Over the last four quarters, the company has surpassed consensus EPS estimates three times [2] - The company posted revenues of $14.19 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.79%, and down from $15.17 million year-over-year [2] Group 2: Stock Performance and Outlook - Citizens Community Bancorp shares have declined approximately 10.9% since the beginning of the year, compared to a decline of 6.1% for the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.31 on revenues of $14.8 million, and $1.31 on revenues of $60.4 million for the current fiscal year [7] Group 3: Industry Context - The Financial - Savings and Loan industry, to which Citizens Community Bancorp belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current status of estimate revisions for Citizens Community Bancorp is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]

Core Viewpoint - Zoetis, Inc. is expected to report its first-quarter 2025 earnings on May 6, 2025, with revenue estimates at $2.19 billion and earnings at $1.40 per share [1]. Group 1: Revenue Sources - The company generates most of its revenues from a diversified portfolio of veterinary medicines and vaccines for livestock and companion animals, with additional revenues from non-pharmaceutical categories like nutritional products and precision animal health services [2]. - In the United States segment, revenues are projected to increase to $1.19 billion, driven by rising sales of companion animal products, with model estimates at $1.17 billion [3]. - The International segment is also expected to see revenue growth, estimated at $0.99 billion, with model estimates at $1.01 billion, primarily due to higher sales of companion animal products [4]. Group 2: Product Performance - Sales of companion animal products, particularly monoclonal antibodies for osteoarthritis pain (Librela for dogs and Solensia for cats), and the flea, tick, and heartworm combination product Simparica Trio, are anticipated to drive revenue growth in both segments [5]. - The FDA recently approved a new indication for Simparica Trio, enhancing its market position as the only canine combination parasiticide indicated to prevent flea tapeworm infections, which is expected to boost future sales [7]. - Livestock product sales in the U.S. are expected to decline due to the divestiture of certain product lines, while international livestock sales are projected to rise, driven by price increases in cattle and poultry portfolios [8]. Group 3: Earnings Surprise History - Zoetis has a strong earnings surprise history, surpassing estimates in the last four quarters with an average surprise of 4.53%, including a 2.19% surprise in the last reported quarter [10]. - The current Earnings ESP for Zoetis is -1.15%, indicating that the most accurate estimate of $1.38 per share is lower than the consensus estimate of $1.40 per share [12].

Core Viewpoint - Columbia Sportswear Company (COLM) is expected to report a decline in both revenues and earnings for the first quarter of 2025, with revenues estimated at $761.9 million, reflecting a 1.1% decrease year-over-year [1]. Revenue Expectations - The Zacks Consensus Estimate for first-quarter revenues is $761.9 million, indicating a 1.1% decrease from the previous year, aligning with the company's guidance of a 1-3% decline, projecting net sales between $749 million and $764 million [1][2]. - The decline in revenues is attributed to the absence of last year's unusually cold winter, which had temporarily boosted demand, and a return to normalized shipping patterns after accelerated shipments in the previous year [2]. Earnings Projections - The consensus estimate for first-quarter earnings per share is stable at 69 cents, representing a 2.8% decline from the year-ago period, with management guiding earnings between 62 cents and 70 cents per share [2]. - Columbia Sportswear has delivered an average earnings surprise of 36.7% over the trailing four quarters [2]. Market Conditions - The company is facing a challenging U.S. market characterized by softened consumer demand, although it has seen stronger performance internationally, particularly in China and the EMEA region [3]. Operating Margin Insights - The projected operating margin for the first quarter is between 5.4% and 6%, with a midpoint of 5.7%, which is a decrease of 10 basis points from the same quarter last year [4]. Strategic Initiatives - Columbia Sportswear's product innovation, ACCELERATE Growth Strategy, and cost-saving initiatives are expected to provide some support against the anticipated declines, with efforts to expand premium product lines and enhance marketing investments [5]. Earnings Prediction Model - The Zacks model does not predict an earnings beat for Columbia Sportswear this quarter, as it holds a Zacks Rank of 3 and an Earnings ESP of 0.00% [6].